Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Et fase 1-studie af AB521 i nyrecellekarcinom og andre faste tumorer (ARC-20)

9. november 2026 opdateret af: Arcus Biosciences, Inc.

En fase 1, åben-label, dosiseskalering og dosisudvidelsesundersøgelse, for at undersøge sikkerheden, tolerabiliteten og farmakokinetisk profil af AB521 monoterapi hos deltagere med klarcellet nyrecellekarcinom og andre faste tumorer

The purpose of this study is to evaluate the safety and tolerability of:

  • casdatifan when taken alone in participants with advanced solid tumor malignancies and clear cell renal cell carcinoma (ccRCC) during the dose escalation stage; and
  • casdatifan monotherapy and casdatifan in combination with cabozantinib or zimberelimab or zimberelimab and ipilimumab or tivozanib or ivonescimab or zimberelimab and axitinib in participants with ccRCC in the dose expansion stage.

Studieoversigt

Status

Rekruttering

Betingelser

Intervention / Behandling

Undersøgelsestype

Interventionel

Tilmelding (Anslået)

512

Fase

  • Fase 1

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiekontakt

Studiesteder

      • Camperdown, Australien
        • Ikke rekrutterer endnu
        • Research Site
      • Melbourne, Australien
        • Rekruttering
        • Research Site
      • Sydney, Australien
        • Rekruttering
        • Research Site
    • Alabama
      • Birmingham, Alabama, Forenede Stater, 35294
        • Rekruttering
        • Research Site
    • California
      • San Diego, California, Forenede Stater, 92093
        • Rekruttering
        • Research Site
      • Santa Monica, California, Forenede Stater, 90404
        • Rekruttering
        • Research Site
    • Florida
      • Miami, Florida, Forenede Stater, 33136
        • Rekruttering
        • Research Site
    • Georgia
      • Atlanta, Georgia, Forenede Stater, 30322-1013
        • Rekruttering
        • Research Site
    • Kentucky
      • Louisville, Kentucky, Forenede Stater, 40202
        • Rekruttering
        • Research Site
    • Louisiana
      • New Orleans, Louisiana, Forenede Stater, 70121
        • Rekruttering
        • Research Site
    • Maryland
      • Baltimore, Maryland, Forenede Stater, 21287
        • Rekruttering
        • Research Site
    • Massachusetts
      • Boston, Massachusetts, Forenede Stater, 02215
        • Rekruttering
        • Research Site
    • Michigan
      • Detroit, Michigan, Forenede Stater, 48202
        • Rekruttering
        • Research Site
      • Detroit, Michigan, Forenede Stater, 48201
        • Rekruttering
        • Research Site
    • Nebraska
      • Omaha, Nebraska, Forenede Stater, 68124
        • Rekruttering
        • Research Site
    • New York
      • New York, New York, Forenede Stater, 10065
        • Rekruttering
        • Research Site
      • New York, New York, Forenede Stater, 10029
        • Rekruttering
        • Research Site
    • Ohio
      • Cleveland, Ohio, Forenede Stater, 44106
        • Rekruttering
        • Research Site
      • Cleveland, Ohio, Forenede Stater, 44195
        • Rekruttering
        • Research Site
    • Pennsylvania
      • Pittsburgh, Pennsylvania, Forenede Stater, 15232
        • Rekruttering
        • Research Site
    • Tennessee
      • Nashville, Tennessee, Forenede Stater, 37203
        • Rekruttering
        • Research Site
      • Nashville, Tennessee, Forenede Stater, 37240
        • Rekruttering
        • Research Site
    • Texas
      • San Antonio, Texas, Forenede Stater, 78229
        • Rekruttering
        • Research Site
      • Barcelona, Spanien
        • Rekruttering
        • Research Site
      • Seoul, Sydkorea
        • Rekruttering
        • Research Site

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

18 år og ældre (Voksen, Ældre voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Beskrivelse

Key Inclusion Criteria:

  • Must have at least one measurable lesion per RECIST guidance

  • Eastern Cooperative Oncology Group (ECOG) performance status score of ≤ 1

  • Disease-specific criteria for dose escalation:

    • Participants may have any pathologically confirmed solid tumor type where no other treatment options are available
    • Creatinine clearance ≥ 40 mL/min

Disease-specific criteria for dose-expansion:

  • Histologically confirmed ccRCC
  • Creatinine clearance ≥ 40 mL/min

Key Exclusion Criteria:

  • Use of any live vaccines against infectious diseases (eg, influenza, varicella) within 4 weeks (28 days) of initiation of investigational product
  • Has any other clinically significant cardiac, respiratory, or other medical or psychiatric condition that might interfere with a participant's participation in the clinical study or make the administration of investigational product hazardous
  • History of trauma or major surgery within 28 days prior to the first dose of investigational product
  • For all expansion cohorts: prior treatment with an hypoxia inducible factor (HIF)-2α inhibitor (except for the tivozanib +/- casdatifan cohort). For the casdatifan + cabozantinib combination cohort, any prior treatment with cabozantinib. For casdatifan + zimberelimab and casdatifan + zimberelimab + ipilimumab cohorts, any prior systemic treatment when cancer is present.
  • Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial

Note: Other protocol defined Inclusion/Exclusion criteria may apply.

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Behandling
  • Tildeling: Ikke-randomiseret
  • Interventionel model: Sekventiel tildeling
  • Maskning: Ingen (Åben etiket)

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Eksperimentel: Dose Escalation Cohort 1

Participants will receive casdatifan orally once daily

Administered as specified in the treatment arm

Andre navne:
  • AB521
Eksperimentel: Dose Escalation Cohort 2

Participants will receive casdatifan orally once daily

Administered as specified in the treatment arm

Andre navne:
  • AB521
Eksperimentel: Dose Escalation Cohort 3

Participants will receive casdatifan orally twice daily

Administered as specified in the treatment arm

Andre navne:
  • AB521
Eksperimentel: Dose Escalation Cohort 4

Participants will receive casdatifan orally once daily

Administered as specified in the treatment arm

Andre navne:
  • AB521
Eksperimentel: Dose Escalation Cohort 5

Participants will receive casdatifan orally once daily

Administered as specified in the treatment arm

Andre navne:
  • AB521
Eksperimentel: Dose Expansion Cohort 1

Participants will receive casdatifan orally

Administered as specified in the treatment arm

Andre navne:
  • AB521
Eksperimentel: Dose Expansion Cohort 2

Participants will receive casdatifan orally

Administered as specified in the treatment arm

Andre navne:
  • AB521
Eksperimentel: Dose Expansion Cohort 3

Participants will receive casdatifan orally

Administered as specified in the treatment arm

Andre navne:
  • AB521
Eksperimentel: Dose Expansion Cohort 4

Participants will receive casdatifan orally with with cabozantinib orally

Administered as specified in the treatment arm

Administered as specified in the treatment arm

Andre navne:
  • AB521
Eksperimentel: Dose Expansion Cohort 5

Participants will receive casdatifan orally

Administered as specified in the treatment arm

Andre navne:
  • AB521
Eksperimentel: Dose Expansion Cohort 6

Participants will receive casdatifan orally

Administered as specified in the treatment arm

Andre navne:
  • AB521
Eksperimentel: Dose Expansion Cohort 7

Participants will receive casdatifan orally with zimberelimab infusion

Administered as specified in the treatment arm

Andre navne:
  • AB122

Administered as specified in the treatment arm

Andre navne:
  • AB521
Eksperimentel: Dose Expansion Cohort 8

Participants will receive casdatifan orally

Administered as specified in the treatment arm

Andre navne:
  • AB521
Eksperimentel: Dose Expansion Cohort 9

Participants will receive casdatifan orally with zimberelimab infusion and ipilimumab infusion

Administered as specified in the treatment arm

Andre navne:
  • AB122

Administered as specified in the treatment arm

Administered as specified in the treatment arm

Andre navne:
  • AB521
Eksperimentel: Dose Expansion Cohort 10

Participants will receive casdatifan orally with zimberelimab infusion and ipilimumab infusion

Administered as specified in the treatment arm

Andre navne:
  • AB122

Administered as specified in the treatment arm

Administered as specified in the treatment arm

Andre navne:
  • AB521
Eksperimentel: Dose Expansion Cohort 11

Participants will receive casdatifan orally with tivozanib orally or tivozanib orally only.

Administered as specified in the treatment arm

Andre navne:
  • AB521

Administered as specified in the treatment arm

Eksperimentel: Dose Expansion Cohort 12

Participants will receive casdatifan orally with ivonescimab infusion.

Administered as specified in the treatment arm

Andre navne:
  • AB521

Administered as specified in the treatment arm

Eksperimentel: Dose Expansion Cohort 13

Participants will receive casdatifan orally with zimberelimab infusion and axitinib orally.

Administered as specified in the treatment arm

Andre navne:
  • AB122

Administered as specified in the treatment arm

Andre navne:
  • AB521

Administered as specified in the treatment arm

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Tidsramme
Antal deltagere med dosisbegrænsende toksicitet (DLT'er)
Tidsramme: Op til 4 måneder
Op til 4 måneder
Antal deltagere med uønskede hændelser (AE'er)
Tidsramme: Op til 4 måneder
Op til 4 måneder

Sekundære resultatmål

Resultatmål
Tidsramme
Objektiv responsrate målt ved responsevalueringskriterier i solide tumorer (RECIST) v1.1
Tidsramme: Op til 4 måneder
Op til 4 måneder
Plasmakoncentration af casdatifan
Tidsramme: Op til 4 måneder
Op til 4 måneder
Areal under plasmakoncentrationstidskurven (AUC) for casdatifan
Tidsramme: Op til 4 måneder
Op til 4 måneder
Maksimal observeret plasmakoncentration (Cmax) af casdatifan
Tidsramme: Op til 4 måneder
Op til 4 måneder
Duration of Response as measured by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1
Tidsramme: Up to 4 months
Up to 4 months
Progression-free survival as measured by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1
Tidsramme: Up to 4 months
Up to 4 months
Overall survival
Tidsramme: Up to 4 months
Up to 4 months
Area under the plasma concentration time curve (AUC) of casdatifan in combination with tivozanib
Tidsramme: Up to 4 months
Up to 4 months
Maximum Observed Plasma Concentration (Cmax) of casdatifan in combination with tivozanib
Tidsramme: Up to 4 months
Up to 4 months
Area under the plasma concentration time curve (AUC) of casdatifan in combination with ivonescimab
Tidsramme: Up to 4 months
Up to 4 months
Maximum Observed Plasma Concentration (Cmax) of casdatifan in combination with ivonescimab
Tidsramme: Up to 4 months
Up to 4 months
Percentage of patients who are ADA-positive and ADA-negative against ivonescimab
Tidsramme: Up to 4 months
Up to 4 months
Area under the plasma concentration time curve (AUC) of casdatifan in combination with zimberelimab and axitinib
Tidsramme: Up to 4 months
Up to 4 months
Maximum Observed Plasma Concentration (Cmax) of casdatifan in combination with zimberelimab and axitinib
Tidsramme: Up to 4 months
Up to 4 months

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Sponsor

Samarbejdspartnere

Efterforskere

  • Studieleder: Medical Director, Arcus Biosciences

Publikationer og nyttige links

Den person, der er ansvarlig for at indtaste oplysninger om undersøgelsen, leverer frivilligt disse publikationer. Disse kan handle om alt relateret til undersøgelsen.

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

26. oktober 2022

Primær færdiggørelse (Anslået)

1. marts 2029

Studieafslutning (Anslået)

1. marts 2029

Datoer for studieregistrering

Først indsendt

7. september 2022

Først indsendt, der opfyldte QC-kriterier

7. september 2022

Først opslået (Faktiske)

10. september 2022

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

13. november 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

9. november 2026

Sidst verificeret

1. april 2026

Mere information

Begreber relateret til denne undersøgelse

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

JA

IPD-planbeskrivelse

Arcus will provide access to individual de-identified participant data and related study documents [e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)] upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions.

For more information, please visit our website.

IPD-deling Understøttende informationstype

  • STUDY_PROTOCOL
  • SAP
  • CSR

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ja

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .